MYC-Hyperactivated Osteosarcoma Models Show Therapy Resistance
Preclinical models demonstrate that MYC-hyperactivated osteosarcoma exhibits resistance to treatment with cabozantinib combined with TIGIT blockade.
Preclinical models demonstrate that MYC-hyperactivated osteosarcoma exhibits resistance to treatment with cabozantinib combined with TIGIT blockade.